The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Page 28

More JCP Articles

JCP
Optimizing Women's Health: Mood Disorders Through Lifespan
Academic Highlights

September 18, 2023

Mood disorders throughout women’s reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.
,
JCP
THC for Neuropsychiatric Symptoms of Dementia
Original Research

September 18, 2023

Neuropsychiatric symptoms (NPS) in dementia are challenging to manage, and available treatments have a significant side effect profile. This study evaluated the effectiveness of dispensary-obtained tetrahydrocannabinol for patients with…
, , , et al
JCP
Excess Mortality Associated With Schizophrenia
Original Research

September 13, 2023

Females, patients with connective tissue disorders, and those aged 20 years or younger were especially impacted by the effect of schizophrenia on increasing mortality.
, , , et al
JCP
Coprescribing of Z-Drugs and Opioids During COVID-19
Original Research

September 11, 2023

Coprescribing of nonbenzodiazepine sedative-hypnotics, or “Z-drugs,” with opioids was more common among older patients, although the odds of coprescription among patients overall decreased over the COVID-19 lockdown period.
, , , et al
JCP
Mortality Within 1 Year After Suicide Attempt
Original Research

September 11, 2023

One in 100 people who attempted suicide died by suicide within 1 year; men aged 45 years or older were at greater risk than other demographic groups.
, , , et al
JCP
Risk-Sensitive Decision-Making and Self-Harm
Original Research

September 6, 2023

Greater risk-taking has been associated with suicide attempts in youth with major depression. This study examined whether the association between self-harm and risk-sensitive decision-making is true for bipolar disorder…
, , , et al
JCP
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
Original Research

September 4, 2023

A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically…
, , , et al
JCP
Omega-3 PUFA Supplements for ADHD
Meta-Analysis

August 30, 2023

Although omega-3 polyunsaturated fatty acids (PUFAs) may not improve core symptoms of attention-deficit/hyperactivity disorder, longer-term PUFA supplementation may have potential benefits.
, , , et al
JCP
Brexpiprazole in Patients With MDD and Prediabetes
Original Research

August 28, 2023

Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic…
, , , et al
JCP
Alcohol Use Disorder Treatment in Sexually and Gender Diverse Patients
Original Research

August 28, 2023

Sexually and gender diverse (SGD) patients had significantly higher rates of both AUD diagnosis and care utilization compared with non-SGD patients.
, , , et al
JCP
Clozapine Delay and Schizophrenia Outcomes
Original Research

August 23, 2023

Clozapine is the drug of choice for treatment-resistant schizophrenia, but delays in initiation and underutilization may hinder its effectiveness. This study examined whether delay in clozapine initiation led to…
, , , et al
JCP
COVID-19 Delirium and Motoric Subtypes: Improving Outcomes
Commentary

August 21, 2023

Randall T. Espinoza, MD, and Aaron Kaufman, MD, discuss a study by Trevisan et al and reflect on lessons learned during the pandemic about detecting and managing delirium.
,

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure shows a syringe and vials with title on aripiprazole monohydrate LAI use in schizophrenia and a red READ NOW button.

Subscribe to read
more articles

Subscribe